Open AccessIs There a Role for Bevacizumab in the Treatment of Glioblastoma?
Author(s) -
Chi Andrew S.,
Chamberlain Marc C.
Publication year - 2013
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2013-0296
Subject(s) - bevacizumab , glioblastoma , medicine , food and drug administration , oncology , clinical trial , drug , pharmacology , chemotherapy , cancer research
Bevacizumab gained accelerated approval from the U.S. Food and Drug Administration for use as monotherapy in progressive glioblastoma, based on improved radiologic response rates observed with bevacizumab monotherapy in two single‐arm or noncomparative phase II trials. Drs. Chi and Chamberlain discuss whether the available evidence supports the use of bevacizumab in glioblastomas.